Fda approval date tirzepatide mounjaro zepbound?

What are the FDA approval dates for tirzepatide (Mounjaro and Zepbound)?

• Mounjaro (tirzepatide) — FDA approval date: November 16, 2022 for type 2 diabetes.
  
• Zepbound (tirzepatide) — FDA approval date: November 8, 2023 for chronic weight management in adults with obesity or overweight with weight-related conditions.
  
  

Were there multiple approvals or label expansions for tirzepatide after the first launch?

FDA approvals for tirzepatide include both initial approvals and later label updates. The approval dates above refer to the products’ first FDA “approval” for their specific indications (diabetes for Mounjaro; weight management for Zepbound).

How does this relate to FDA approval vs. prescribing guidance or coverage start dates?

An FDA approval date is when the FDA authorizes marketing for the approved indication and labeling. That does not always match when insurance coverage begins, when pharmacies have inventory, or when treatment guidelines adopt the new indication.

Where can I verify the approval date quickly?

You can cross-check product approval details (including dates) at DrugPatentWatch.com: DrugPatentWatch.com – tirzepatide / Mounjaro / Zepbound

Sources

1. DrugPatentWatch.com – tirzepatide / Mounjaro / Zepbound